Document is current

Article History

Received: 21 February 2025

Accepted: 5 August 2025

First Online: 22 September 2025

Competing interests

: D.S.K. reports grant support from Amgen and the Bristol Myers Squibb Foundation (via the Robert A. Winn Excellence in Clinical Trials Career Development Award). F.R. reports equity from Carta Healthcare and HealthPals, and consulting fees from HealthPals, Novartis, Novo Nordisk, Esperion Therapeutics, Movano Health, Kento Health, Inclusive Health, Edwards, Arrowhead Pharmaceuticals, HeartFlow, and iRhythm outside the submitted work. E.A.A. reports advisory board fees from SequenceBio, Foresite Labs, Pacific Biosciences, and Versant Ventures. E.A.A. has ownership interest in Personalis, Deepcell, Svexa, Candela, Parameter Health, Saturnus Bio, outside the submitted work. E.A.A. is a non-executive director of AstraZeneca and Svexa. E.A.A. receives collaborative research support from Illumina, Pacific Biosciences, Oxford Nanopore, Cache, Cellsonics, outside the submitted work. The remainder of the authors report no potential conflicts of interest. S.M., A.J., M.O., N.S., A.T., R.D., C.M.M., A.L., M.R.-P., P.S., E.L., and A.C.K. declare no competing interests.